Loading people...
Dr. Regina Hodits is a Managing Director at Angelini Ventures and a Venture Advisor at Wellington Partners, based in Munich, Germany. Before assuming her current positions in 2025, she served as a Managing Partner at Wellington Partners, where she co-led the €210 million Life Science Fund VI and executed more than 25 investments. Her portfolio track record includes founding investments in Bicycle Therapeutics and successful exits such as the acquisitions of Themis and Rigontec by MSD, as well as Sapiens by Medtronic. Earlier in her career, she worked as a Consultant at McKinsey & Company, an Investment Manager at Apax Partners, and a Partner leading European life sciences at Atlas Venture. Holding a doctorate in biochemistry from the University of Vienna, her investment focus remains centered on early-stage biotechnology, diagnostics, and medical device companies.
Dr. Regina Hodits stands as a prominent figure in the European venture capital landscape, serving as a Managing Partner at Wellington Partners. Her leadership at this esteemed firm underscores her deep expertise and strategic vision in identifying and nurturing groundbreaking companies. Wellington Partners, under her guidance, continues to be a pivotal force in supporting the next generation of innovators.
As a Managing Partner, Dr. Hodits plays a crucial role in shaping Wellington Partners' investment strategy, particularly in the early-stage deep tech and life sciences sectors. Her investment focus is primarily directed towards disruptive technologies within biotech, digital health, and other advanced scientific fields. She seeks out companies that are poised to revolutionize their respective industries, often at the seed or Series A stage, providing not just capital but also invaluable strategic guidance and mentorship.
Dr. Hodits' career background is distinguished by a unique blend of scientific rigor and entrepreneurial drive. Prior to joining Wellington Partners in 2010, she held significant positions that honed her understanding of the biotech and pharmaceutical industries. Her journey includes roles at major pharmaceutical companies like Boehringer Ingelheim, where she gained firsthand experience in drug development and commercialization. Furthermore, her entrepreneurial spirit led her to co-found a biotech startup, giving her a founder's perspective on the challenges and triumphs of building a company from the ground up. This diverse experience, coupled with her Ph.D. in molecular biology, provides her with a profound ability to evaluate complex scientific innovations and market potential.
Throughout her tenure at Wellington Partners, Dr. Regina Hodits has been instrumental in numerous successful investments. Her portfolio reflects a keen eye for transformative ventures. Notable investments include Rigontec, a company focused on immuno-oncology, which was successfully acquired by Merck KGaA. Another significant success is Themis Bioscience, a vaccine development company acquired by MSD. She was also an early backer of Endosense, a medical device company acquired by Boston Scientific, and has supported innovative firms like Immatics, CatalYm, and iOmx Therapeutics. These investments highlight her commitment to backing companies that deliver significant scientific advancements and strong commercial outcomes, solidifying her reputation as a leading investor in European deep tech and life sciences.
Dr. Regina Hodits is a Managing Partner at Wellington Partners, a leading European venture capital firm. She is known for her expertise in early-stage investments, particularly in deep tech, life sciences, and digital health.
Dr. Regina Hodits primarily invests in early-stage (seed and Series A) disruptive deep tech, life sciences, and digital health companies across Europe. Her focus areas include biotech, advanced therapeutics, and innovative medical technologies.
Dr. Regina Hodits works as a Managing Partner at Wellington Partners, a prominent venture capital firm with offices in Munich, Germany, and London, UK. She plays a key role in their European investment activities.
